Recent Updates
Recently added Catalysts
ACRS

Aclaris Therapeutics to Announce Third Quarter 2017 Financial Results on November 7, 2017

Key Takeaway: MALVERN, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its third quarter financial results before the market open on November 7, 2017 Management will conduct a conference call at 8:00 AM ET t

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis

Full Press Release Details

MALVERN, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its third quarter financial results before the market open on November 7, 2017
Management will conduct a conference call at 8:00 AM ET that day to discuss the Company’s financial results and provide a general business update. A live webcast of the event can be accessed on the Events and Presentations page on the Investors section of the Aclaris website at http://www.aclaristx.com/events-and-webcasts. A replay of the webcast will be archived on the Aclaris website following the event.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 99295180 prior to the start of the call.
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Last updated: Oct 31, 2017